{"filing":{"accession_number":"0001628280-26-067129","cik":"0001576885","ticker":"ABOS","company_name":"Acumen Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-26","primary_document":"abos-20261026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/abos-20261026.htm"},"events":[{"id":37793,"run_id":34832,"accession_number":"0001628280-26-067129","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Acumen Pharmaceuticals disclosed third quarter 2026 financial results on October 26, 2026, reporting R\u0026D expenses of $21.1 million, G\u0026A expenses of $4.7 million, net loss of $25.4 million, and cash position of $78.6 million as of September 30, 2026, along with business highlights regarding the ALTITUDE-AD Phase 2 trial and EBD program milestones.","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42628,"accession_number":"0001628280-26-067129","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Acumen Pharmaceuticals disclosed third quarter 2026 financial results on October 26, 2026, including R\u0026D expenses of $21.1 million, G\u0026A expenses of $4.7 million, net loss of $25.4 million, and cash position of $78.6 million as of September 30, 2026. The press release (Exhibit 99.1) is a standard earnings announcement with condensed balance sheets, statements of operations, and cash flow statements, accompanied by business highlights regarding the ALTITUDE-AD Phase 2 trial and EBD program milestones. This is a typical Item 2.02 earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T11:10:41.596311+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42629,"accession_number":"0001628280-26-067129","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes an updated corporate presentation, but the substantive content disclosed in the attached exhibits (EX-99.1 and EX-99.2) constitutes an earnings release. EX-99.1 is explicitly titled \"Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights\" and includes Q3 2026 condensed financial statements (balance sheet, statements of operations, and cash flows), along with key operational milestones and management commentary. This is a classic earnings release disclosure, material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T11:10:41.596311+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42628,"accession_number":"0001628280-26-067129","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Acumen Pharmaceuticals disclosed third quarter 2026 financial results on October 26, 2026, including R\u0026D expenses of $21.1 million, G\u0026A expenses of $4.7 million, net loss of $25.4 million, and cash position of $78.6 million as of September 30, 2026. The press release (Exhibit 99.1) is a standard earnings announcement with condensed balance sheets, statements of operations, and cash flow statements, accompanied by business highlights regarding the ALTITUDE-AD Phase 2 trial and EBD program milestones. This is a typical Item 2.02 earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T11:10:41.596311+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-10-26"},{"id":42629,"accession_number":"0001628280-26-067129","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes an updated corporate presentation, but the substantive content disclosed in the attached exhibits (EX-99.1 and EX-99.2) constitutes an earnings release. EX-99.1 is explicitly titled \"Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights\" and includes Q3 2026 condensed financial statements (balance sheet, statements of operations, and cash flows), along with key operational milestones and management commentary. This is a classic earnings release disclosure, material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T11:10:41.596311+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-10-26"}]}
